OHE together with York, Manchester and Imperial have been awarded a grant from the NIHR PRP to evaluate the PSS Commissioning for Quality and Innovation (CQUIN) schemes.
This blog post discusses the role of social value judgements in NICE technology appraisals, focusing on the recent appraisal of dinutuximab beta for high-risk neuroblastoma.
